Brief: Kronos Bio Announces Prioritization Of Clinical Portfolio To Focus On Lanraplenib, KB-0742
08/11/2022 23:17
Nov 8 (Reuters) - Kronos Bio Inc KRON.O :
* KRONOS BIO ANNOUNCES PRIORITIZATION OF CLINICAL PORTFOLIO
TO
FOCUS ON LANRAPLENIB AND KB-0742
* KRONOS BIO - WITH $270.3 MILLION IN CASH, CASH EQUIVALENTS
AND
INVESTMENTS AS OF SEPT. 30, 2022, CO EXTENDS EXPECTED CASH
RUNWAY FROM Q4 2024 INTO Q2 2025
Source text for Eikon: ID:nGNXbWwFzK
Further company coverage: KRON.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kronos Bio
See all newsBrief: Kronos Bio Inc - Terminates Office Lease At 301 Binney Street - SEC Filing
Brief: Kronos Bio Inc - Enters Transition Agreement With Genentech
U.S. STOCKS ON THE MOVE - Ambarella, Dell, Nordstrom
U.S. STOCKS ON THE MOVE - Golden Ocean, Guess, Symbotic
U.S. STOCKS ON THE MOVE-HP, Urban Outfitters, 3D Systems